Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Bausch & Lomb gets option to Mimetogen's Phase II dry eye syndrome candidate; option period has expired

05 Nov 2015

Executive Summary

Eye health giant Bausch & Lomb Inc., which is in the process of being acquired by Valeant Pharmaceuticals International Inc. for $8.7bn, has received an option to license exclusive worldwide rights to the Phase II dry eye syndrome (DES) candidate MIMD3 from Mimetogen Pharmaceuticals Inc.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By